Why dried blood spots are an ideal tool for CYP1A2 phenotyping

Clinical Pharmacokinetics

Volumn 53, Issue 8, 2014, Pages 763-771

  De Kesel, Pieter M M ^a   Lambert, Willy E ^a   Stove, Christophe P ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE; 1,7-DIMETHYLXANTHINE; CYP1A2 PROTEIN, HUMAN; THEOPHYLLINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD VOLUME; CAPILLARY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VENOUS BLOOD; BLOOD; METABOLISM; MIDDLE AGED; PROCEDURES; REGRESSION ANALYSIS; YOUNG ADULT;

ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; DRIED BLOOD SPOT TESTING; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; REGRESSION ANALYSIS; THEOPHYLLINE; YOUNG ADULT;

EID: 84905012788     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0150-5     Document Type: Article

References (37)

1. Demirev PA. Dried blood spots: analysis and applications. Anal Chem. 2013;85(2):779-89.
2. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327-36.
3. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49-65.
4. Meesters RJ, Hooff GP. State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. Bioanalysis. 2013;5(17):2187-208.
5. Stove CP, Ingels AS, De Kesel PM, Lambert WE. Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol. 2012;42(3):230-43.
6. ®)-treated narcoleptic patients using dried blood spot sampling at home: an exploratory study. CNS Drugs. 2013;27(3):233-7.
7. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66(7):705-12.
8. Mohammed BS, Cameron GA, Cameron L, Hawksworth GH, Helms PJ, Mclay JS. Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol? Brit J Clin Pharmacol. 2010;70(1):52-6.
9. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 2010;12(3):290-3.
10. De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis. 2013;5(16):2023-41.
11. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2(8):1385-95.
12. O'Mara M, Hudson-Curtis B, Olson K, Yueh Y, Dunn J, Spooner N. The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis. 2011;3(20):2335-47.
13. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12(8):707-47.
14. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52-62.
15. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131-44.
16. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41.
17. Kalow W, Tang BK. The use of caffeine for enzyme assays - a critical appraisal. Clin Pharmacol Ther. 1993;53(5):503-14.
18. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007;81(2):270-83.
19. Perera V, Gross AS, McLachlan AJ. Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr Drug Metab. 2012;13(5):667-78.
20. de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25(10):1112-23.
21. Daali Y, Samer C, Deglon J, Thomas A, Chabert J, Rebsamen M, et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther. 2012;91(3):489-96.
22. Bosilkovska M, Deglon J, Samer C, Walder B, Desmeules J, Staub C, et al. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis. 2014;6(2):151-64.
23. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S, et al. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271-82.
24. De Kesel PM, Lambert WE, Stove CP. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis. In Press.
25. European Medicines Agency. Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 08/WC500150010.pdf. Accessed Mar 2014.
26. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Veterinary Medicine. Draft Guidance for Industry. Bioanalytical Method Validation. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm368107.pdf. Accessed Mar 2014.
27. Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem. 2013;85(1):404-10.
28. Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63(9):1161-8.
29. Dewitte K, Fierens C, Stockl D, Thienpont LM. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. Clin Chem. 2002;48(5):799-801.
30. Rainey PM. Relation between serum and whole-blood ethanol concentrations. Clin Chem. 1993;39(11):2288-92.
31. Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II). Clin Pharmacokinet. 1989;17(4):275-90.
32. Holub M, Tuschl K, Ratschmann R, Strnadova KA, Muhl A, Heinze G, et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta. 2006;373(1-2):27-31.
33. Ingels AS, De Paepe P, Anseeuw K, Van Sassenbroeck D, Neels H, Lambert W, et al. Dried blood spot punches for confirmation of suspected gamma-hydroxybutyric acid intoxications: validation of an optimized GC-MS procedure. Bioanalysis. 2011;3(20):2271-81.
34. Mess JN, Taillon MP, Cote C, Garofolo F. Dried blood spot on-card derivatization: an alternative form of sample handling to overcome the instability of thiorphan in biological matrix. Biomed Chromatogr. 2012;26(12):1617-24.
35. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(15-16):1063-70.
36. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90(1):117-25.
37. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11(5):429-35.